We are live on !
Find out more
Birchview Capital Portfolio holdings
AUM
$214M
Turnover
33.33%
1-Year Est. Return
185.33%
This Fund
S&P 500
This Quarter Est. Return
+0.74%
1 Year Est. Return
+185.33%
3 Year Est. Return
+327.48%
5 Year Est. Return
+458.62%
10 Year Est. Return
+1,549.55%
AUM
$138M
AUM Growth
-$2.5M
(-1.8%)
Cap. Flow
-$444K
Cap. Flow % of AUM
Cap. Flow %
-0.32%
Top 10 Holdings %
Top 10 Hldgs %
90.14%
Holding
46
New
6
Increased
1
Reduced
1
Closed
1
Avg Time Held
1
year
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RLYP
RELYPSA INC COM
RLYP
|
+$316K |
| 2 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
+$164K |
| 3 |
Seres Therapeutics
MCRB
|
+$147K |
| 4 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$139K |
| 5 |
Workhorse Group
WKHS
|
+$118K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Collegium Pharmaceutical
COLL
|
+$1.39M |
| 2 |
Kura Oncology
KURA
|
+$62.2K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.54% |
| 2 | Energy | 3.85% |
| 3 | Miscellaneous | 3.15% |
| 4 | Consumer Staples | 1.23% |
| 5 | Technology | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $76.8M | 55.78% |
779,051
| – | – |
2014 Q4
6 quarters
|
|
2
DELISTED
Accelerate Diagnostics
AXDX
| $31.3M | 22.73% |
217,580
| – | – |
2014 Q4
6 quarters
|
|
3
EQT Corp
EQT
$31B
| $3.28M | 2.38% |
77,705
| – | – |
2014 Q4
6 quarters
|
|
|
VRML
4
DELISTED
Vermillion, Inc.
VRML
| $3.02M | 2.19% |
2,717,514
| – | – |
2014 Q4
6 quarters
|
|
|
HNSN
5
DELISTED
HANSEN MEDICAL, INC. COM NEW
HNSN
| $2.1M | 1.52% |
528,142
| – | – |
2014 Q4
6 quarters
|
|
6
DELISTED
Masimo
MASI
| $1.92M | 1.4% |
36,600
| – | – |
2014 Q4
6 quarters
|
|
7
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
| $1.69M | 1.23% |
236
| – | – |
2014 Q4
6 quarters
|
|
8
DELISTED
Biolase, Inc.
BIOL
| $1.5M | 1.09% |
103
| – | – |
2014 Q4
6 quarters
|
|
|
CFRX
9
DELISTED
ContraFect Corporation
CFRX
| $1.37M | 1% |
594
| – | – |
2015 Q2
4 quarters
|
|
10
Neurocrine Biosciences
NBIX
$17B
| $1.14M | 0.83% |
25,200
| – | – |
2015 Q3
3 quarters
|
|
|
MDVN
11
DELISTED
MEDIVATION, INC.
MDVN
| $1.13M | 0.82% |
18,760
| – | – |
2014 Q4
6 quarters
|
|
12
Ovintiv
OVV
$16.1B
| $1.03M | 0.75% |
26,460
| – | – |
2014 Q4
6 quarters
|
|
|
OMED
13
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $870K | 0.63% |
70,689
| – | – |
2014 Q4
6 quarters
|
|
14
Merck
MRK
$366B
| $864K | 0.63% |
15,720
| – | – |
2014 Q4
6 quarters
|
|
|
TSRO
15
DELISTED
TESARO, Inc.
TSRO
| $710K | 0.52% |
8,450
+1,500
| +22% | +$66.9K |
2015 Q4
2 quarters
|
|
16
QuidelOrtho
QDEL
$810M
| $696K | 0.51% |
38,975
| – | – |
2014 Q4
6 quarters
|
|
|
NXTM
17
DELISTED
NxStage Medical Inc.
NXTM
| $611K | 0.44% |
28,200
| – | – |
2014 Q4
6 quarters
|
|
18
DELISTED
Coterra Energy
CTRA
| $541K | 0.39% |
21,000
| – | – |
2014 Q4
6 quarters
|
|
|
WMGI
19
DELISTED
Wright Medical Group Inc
WMGI
| $521K | 0.38% |
30,000
| – | – |
2015 Q4
2 quarters
|
|
|
OXFD
20
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $507K | 0.37% |
56,303
| – | – |
2015 Q3
3 quarters
|
|
21
Accuray
ARAY
$11.3M
| $495K | 0.36% |
2,383
| – | – |
2014 Q4
6 quarters
|
|
22
DELISTED
Pioneer Natural Resource Co.
PXD
| $456K | 0.33% |
3,000
| – | – |
2014 Q4
6 quarters
|
|
|
QTNT
23
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $451K | 0.33% |
1,455
| – | – |
2014 Q4
6 quarters
|
|
24
Corcept Therapeutics
CORT
$8.13B
| $437K | 0.32% |
80,000
| – | – |
2015 Q4
2 quarters
|
|
|
SIEN
25
DELISTED
Sientra, Inc.
SIEN
| $417K | 0.3% |
6,330
| – | – |
2015 Q3
3 quarters
|
|
Similar funds
SF
Birchview Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Birchview Capital held 46 positions worth $138M, down 1.8% from $140M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Birchview Capital's Q2 2016 filing shows 6 new, 1 increased, 1 reduced and 1 closed positions. Its largest new stake was RELYPSA INC COM: 18,000 shares worth $333K. The largest sale was Collegium Pharmaceutical, an estimated $1.39M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Energy and Miscellaneous.
- Birchview Capital's largest Q2 2016 buy was RELYPSA INC COM: 18,000 shares worth $333K.
- Birchview Capital added most to TESARO, Inc. in Q2 2016, an estimated $66.9K increase.
- Birchview Capital's biggest Q2 2016 reduction was Kura Oncology, cutting an estimated $62.2K.
- Birchview Capital fully exited Collegium Pharmaceutical in Q2 2016, selling an estimated $1.39M.
- Birchview Capital's ten largest holdings make up 90% of its $138M portfolio in Q2 2016.
- Birchview Capital opened 6 new positions and closed 1 in Q2 2016.
- Birchview Capital's portfolio value fell 1.8% quarter-over-quarter to $138M.
Based on Birchview Capital's 13F filing for Q2 2016, filed 9 Aug 2016.